Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,531 Mln
Revenue (TTM)
$643 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3
Industry P/E
--
EV/EBITDA
489.4
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$6.4
EPS
$-0.3
Face value
--
Shares outstanding
117,673,382
CFO
$-340.56 Mln
EBITDA
$-508.93 Mln
Net Profit
$-1,184.55 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
10X Genomics Inc (TXG)
| 36.9 | -3.1 | 36.9 | 157.6 | -26.3 | -34.5 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
10X Genomics Inc (TXG)
| 13.6 | -74.1 | 53.6 | -75.5 | 5.2 | 85.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
10X Genomics Inc (TXG)
|
22.3 | 2,530.8 | 642.8 | -43.5 | -3.8 | -5.8 | -- | 3.0 |
| 7.9 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,248.3 | 2,554.2 | 319.2 | 19.5 | 4.7 | 9.6 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers... Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. Address: 6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260 Read more
Co-Founder, CEO & Director
Dr. Serge Saxonov Ph.D.
Co-Founder, CEO & Director
Dr. Serge Saxonov Ph.D.
Headquarters
Pleasanton, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of 10X Genomics Inc (TXG) is $22.33 (NASDAQ) as of 02-Apr-2026 19:54 EDT. 10X Genomics Inc (TXG) has given a return of -26.3% in the last 3 years.
Since, TTM earnings of 10X Genomics Inc (TXG) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-46.82
|
2.56
|
|
2024
|
-9.44
|
2.43
|
|
2023
|
-25.67
|
8.84
|
|
2022
|
-25.03
|
5.16
|
|
2021
|
-281.43
|
20.04
|
The 52-week high and low of 10X Genomics Inc (TXG) are Rs 23.56 and Rs 6.78 as of 04-Apr-2026.
10X Genomics Inc (TXG) has a market capitalisation of $ 2,531 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in 10X Genomics Inc (TXG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.28
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.